-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Initiates Coverage On Bicara Therapeutics with Underweight Rating, Announces Price Target of $8

Benzinga·04/17/2025 12:01:59
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Underweight rating and announces Price Target of $8.